Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3048% below fair value
$1.71+0.09 (+5.56%)
Close on Nov 13, 2026Market cap $14.10MP/E –Yield –
Lipocine profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Lipocine's profit margin for the twelve months ending Sep 30, 2026 was -249.2%. For fiscal 2025 it was -487.1%, against 0.1% the year before. The highest annual figure on record is 50.4% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -487.1% | −487.1 |
| FY2024 | Dec 31, 2024 | 0.1% | +2151.8 |
| FY2022 | Dec 31, 2022 | -2151.7% | −2147.8 |
| FY2021 | Dec 31, 2021 | -3.9% | +7879.8 |
| FY2019 | Dec 31, 2019 | -7883.7% | −5159.6 |
| FY2018 | Dec 31, 2018 | -2724.1% | −2774.5 |
| FY2012 | Dec 31, 2012 | 50.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -29.1% | +2752.4 |
| Q2 FY2026 | Jun 30, 2026 | -1379.6% | −1025.5 |
| Q1 FY2026 | Mar 31, 2026 | -3075.4% | −1088.6 |
| Q4 FY2025 | Dec 31, 2025 | -206.9% | −258.0 |
| Q3 FY2025 | Sep 30, 2025 | -2781.5% | +644.7 |
| Q2 FY2025 | Jun 30, 2025 | -354.1% | −400.3 |
| Q1 FY2025 | Mar 31, 2025 | -1986.8% | −931.1 |
| Q4 FY2024 | Dec 31, 2024 | 51.0% | +7089.1 |
| Q2 FY2024 | Jun 30, 2024 | -3426.2% | −2899.8 |
| Q1 FY2024 | Mar 31, 2024 | 46.1% | −32.4 |
| Q4 FY2023 | Dec 31, 2023 | -1055.7% | +4547.3 |
| Q1 FY2023 | Mar 31, 2023 | -7038.1% | −5183.3 |
| Q2 FY2022 | Jun 30, 2022 | -526.4% | +109.1 |
| Q4 FY2021 | Dec 31, 2021 | 78.5% | – |
| Q3 FY2021 | Sep 30, 2021 | -5603.0% | – |
| Q3 FY2019 | Sep 30, 2019 | -1854.8% | – |
| Q1 FY2018 | Mar 31, 2018 | -635.5% | – |
See a number that looks wrong?